Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Affiliation auteurs!!!! Error affiliation !!!!
TitreObinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
Type de publicationJournal Article
Year of Publication2019
AuteursHouot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas R-O, Molucon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F
JournalLEUKEMIA
Volume33
Pagination776-780
Date PublishedMAR
Type of ArticleArticle
ISSN0887-6924
DOI10.1038/s41375-018-0282-y